NIH-funded research R01 grant

Developing tools to study a specific type of brain immune cell in neurological diseases

Official title: Molecular Tool Development to Identify, Isolate, and Interrogate the Rod Microglia Phenotype in Neurological Disease and Injury

Funded at Arizona Veterans Research and Education Foundation · NIH-11014069 · Data updated 2026-11-12

This study is looking at special immune cells in the brain called rod microglia to learn more about their role in conditions like Alzheimer's, with the hope that this research will help improve how we diagnose and treat these diseases.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionArizona Veterans Research and Education Foundation
NIH-funded
Lab location1 site (Phoenix, United States)
Project startApril 1, 2023
Project endDecember 31, 2026
Funding year2025
Award (this year)$628,748
NIH project number5R01AG077768-03
Project IDNIH-11014069 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with Alzheimer's Disease or related dementias, as well as those who have experienced acquired brain injuries.

Less likely to help

Patients with neurological conditions not related to Alzheimer's Disease or acquired brain injuries may not benefit from this research.

What this research studies

This research focuses on creating new molecular tools to identify and study rod microglia, a unique type of immune cell in the brain that has been linked to various neurological conditions, including Alzheimer's Disease and related dementias. By analyzing these cells, researchers aim to better understand their role in neuroinflammation and brain injury. The study utilizes advanced techniques such as single-cell RNA sequencing to explore the genetic characteristics of rod microglia, which could lead to breakthroughs in diagnosing and treating neurological diseases.

Why it matters

Potential benefit: If successful, this research could lead to improved diagnostic tools and therapeutic strategies for patients with Alzheimer's Disease and related neurological disorders.

How similar studies have gone: While the investigation of rod microglia is relatively novel, previous research has shown promise in understanding microglial roles in other neurological conditions, suggesting potential for success in this area.

Where this research is happening

  • Arizona Veterans Research and Education Foundation
    Phoenix, United States
    Active

Researchers

  • Principal investigator: Lifshitz, Jonathan — Arizona Veterans Research and Education Foundation
  • Study coordinator: Lifshitz, Jonathan

Related research

Other NIH-funded projects on the same topics.

  • Investigating how a peptide affects aging-related dementia

    This study is looking at how a substance called medin, which builds up in our blood vessels as we get older, might be linked to dementia, like Alzheimer's, and aims to find ways to reduce its harmful effects on the brain and blood vessels.

    NIH research Arizona Veterans Research and Education Foundation · Phoenix, United States · NIH-10901026

  • New treatment for vascular aging and related dementias

    This study is testing a new treatment that uses a vaccine and antibodies to help reduce a harmful substance in blood vessels, which could improve brain health and memory for people facing age-related cognitive decline and dementia.

    NIH research Arizona Veterans Research and Education Foundation · Phoenix, United States · NIH-10724869

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.